A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 Weeks in Subjects With Chronic HCV Infection and Child-Pugh-Turcotte Class C Cirrhosis
Phase of Trial: Phase II
Latest Information Update: 10 Apr 2018
At a glance
- Drugs Ribavirin (Primary) ; Sofosbuvir/velpatasvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Sponsors Gilead Sciences
- 04 Apr 2018 Planned primary completion date changed from 1 Sep 2018 to 1 Nov 2018.
- 06 Feb 2018 Planned end date changed from 1 Aug 2018 to 1 Dec 2018.
- 06 Feb 2018 Planned primary completion date changed from 1 May 2018 to 1 Sep 2018.